Evercore ISI initiated coverage of MedinCell (MDCLF) with an Outperform rating and no price target The French biotech company specializing in long-acting injectable formulation technology earns revenue through royalties on worldwide net sales of partnered drugs as well as through licensing fees and milestones and has become “an increasingly popular partner-of-choice” for big pharma companies, the analyst tells investors. Currently partnered with Teva (TEVA) on their LAI atypical antipsychotics used in schizophrenia, Uzedy royalties will get them to profitability in 2027, but the main focus is on LAI olanzapine, which is expected to launch into a market with essentially zero competition in 2026, if approved, the analyst tells investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TEVA:
- Teva Pharmaceutical’s Strategic Edge and Growth Potential: Analyst Recommends Buy Rating
- Teva, Fosun Pharma partner to develop TEV-56278
- Teva, Fosun enter strategic partnership to develop TEV-56278
- Teva put volume heavy and directionally bearish
- Teva ‘well positioned for upside from here,’ says JPMorgan